Telomir Pharmaceuticals (NASDAQ:TELO) Rating Increased to Strong-Buy at Maxim Group

Maxim Group upgraded shares of Telomir Pharmaceuticals (NASDAQ:TELO) to a strong-buy rating in a research report sent to investors on Thursday morning,Zacks reports.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a research note on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $4.00.

Telomir Pharmaceuticals Stock Performance

NASDAQ TELO opened at $1.23 on Thursday. The firm’s fifty day moving average price is $1.15 and its two-hundred day moving average price is $1.25. The stock has a market cap of $84.60 million, a PE ratio of -1.35 and a beta of -0.25. Telomir Pharmaceuticals has a fifty-two week low of $0.89 and a fifty-two week high of $2.09.

Telomir Pharmaceuticals (NASDAQ:TELO) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.72).

Institutional Trading of Telomir Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of TELO. BlackRock Inc. bought a new position in Telomir Pharmaceuticals during the 2nd quarter worth $359,000. Bank of New York Mellon Corp acquired a new stake in shares of Telomir Pharmaceuticals in the second quarter valued at about $66,000. World Investment Advisors bought a new position in shares of Telomir Pharmaceuticals during the fourth quarter worth about $47,000. Finally, OneDigital Investment Advisors LLC bought a new position in shares of Telomir Pharmaceuticals during the second quarter worth about $29,000.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing therapies for diseases and conditions associated with aging. The company’s research is centered on telomere biology, an area involving the protective structures at the ends of chromosomes that generally shorten as cells divide and age.

Telomir’s lead product candidate is TELOMIR-1, an orally administered small-molecule compound being investigated for its potential to address telomere shortening and support healthier cellular aging.